In a report, four patients were reported, out of which three patients (13.5-year-old patient, 10-year-old girl and 3-month-old infant) [not all sexes stated] were described, who developed sinus bradycardia during treatment with remdesivir for COVID-19 pneumonia [routes and dosages not stated and duration of treatments to reactions onset not stated].
All three patients were presented to the paediatric intensive care unit with symptoms of dyspnoea, fever and low oxygen saturation and required oxygen support. Chest radiographs of all patients demonstrated diffuse pulmonary infiltrates. Laboratory investigations showed lymphopaenia. All three patients were diagnosed with COVID-19 pneumonia, and started receiving off label treatment with ampicillin and dexamethasone. Additionally, all patients received treatment with remdesivir. Following administration of fourth dose of remdesivir, the first patient's (13.5-year-old) heart rate decrease to 50 bpm from 80 bpm at baseline. Following administration of third dose of remdesivir, the second patient's (10-year-old girl) heart rate decrease to 60 bpm from 80 bpm at baseline. Following administration of third dose of remdesivir, the third patient's (3-month-old infant) heart rate decrease to 80 bpm from 130 bpm at baseline. All three patients developed asymptomatic sinus bradycardia. In all three patients, otherwise cardiologic evaluation was normal. In the infant (third patient), remdesivir was stoped and in remaining two patients 5-day treatment with remdesivir was completed. Afterwards, heart rate was normalised in all patients. Clinical course was uncomplicated; and subsequently, all patients were discharged home.
